Related Experiment Videos
An alternative aerosol delivery system for amiloride
M L Everard1, S G Devadason, V B Sunderland
1Department of Respiratory Medicine, Princess Margaret Hospital for Children, Perth, Western Australia.
Thorax
|May 1, 1995
Summary
Dry powder amiloride delivered via Turbohaler shows promise for cystic fibrosis treatment. This method offers a more convenient and effective alternative to traditional nebulizers for delivering this important medication.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Drug Delivery Systems
Background:
- Novel treatments like aerosolized amiloride offer potential for cystic fibrosis (CF).
- Current delivery methods (jet nebulizers) are time-consuming, limiting treatment acceptance and efficacy.
- Investigating dry powder amiloride via Turbohaler addresses these limitations.
Purpose of the Study:
- To evaluate the feasibility of delivering micronized amiloride in dry powder form using a Turbohaler.
- To assess the dose delivered per actuation and particle size distribution of amiloride aerosol from the Turbohaler.
Main Methods:
- Micronized amiloride was loaded into 200 microgram Turbohalers.
- Dose and particle size distribution were assessed at a flow rate of 60 L/min.
- Amiloride dose was quantified using ultraviolet spectrophotometry; particle size was measured with a Malvern MasterSizer.
Main Results:
- The mean dose delivered per actuation was 246.3 (40.4) micrograms.
- The volume median diameter of the amiloride aerosol was 3.80 (0.68) microns.
- Particle size was comparable to that of budesonide delivered via Turbohaler.
Conclusions:
- Micronized amiloride can be effectively delivered as a dry powder aerosol using a Turbohaler.
- This dry powder formulation offers a convenient and potentially more efficacious method for amiloride administration in cystic fibrosis patients.